![Prothena Corporation plc logo](/logos/PRTA.webp)
Prothena Corporation plc
NASDAQ:PRTA
Overview | Financials
Company Name | Prothena Corporation plc |
Symbol | PRTA |
Currency | USD |
Price | 20.33 |
Market Cap | 1,093,353,499 |
Dividend Yield | 0% |
52-week-range | 18.69 - 56.04 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Gene G. Kinney Ph.D. |
Website | https://www.prothena.com |
An error occurred while fetching data.
About Prothena Corporation plc
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD